Latest Design of experiments Stories
The Guardian Research Network and Molecular Health will Provide Cancer Patients with Personalized Clinical Decision Support CAMBRIDGE, Massachusetts and SPARTANBURG, South Carolina, May 29,
Will Include Survival Data To Date and Other Findings BETHESDA, Md., May 27, 2015 /PRNewswire/ -- Northwest Biotherapeutics, Inc.
All amounts are in US dollars QUÉBEC CITY, May 26, 2015 /PRNewswire/ - Aeterna Zentaris Inc.
Statistically Significant Findings Identify Key Efficacy Targets for Phase IIb/III Clinical Trial with RGN-259 ROCKVILLE, Md., May 22, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals,
COSTA MESA, Calif., May 18, 2015 /PRNewswire-iReach/ -- California CRO WCCT Global recently completed a study on elderly subjects
Conference call to be held on Thursday, May 14, 2015 at 4:30 p.m. Eastern Time BOTHELL, Wash.
MUMBAI, May 13, 2015 /PRNewswire/ -- During the period April 6th to 8th 2015, Accutest successfully completed its 22nd USFDA inspection without receiving any form 483.
CINCINNATI and DURHAM, N.C., May 12, 2015 /PRNewswire/ -- Schulman Associates IRB, Inc., the industry-leading central IRB in customer service and technology, has announced board expertise and
RYE, N.Y., May 11, 2015 /PRNewswire/ -- Curemark LLC, a privately held drug research and development company, announced the start of a new Phase III double blind, randomized, placebo-controlled
Reaccreditation underscores WIRB-Copernicus Group's commitment to conducting high-quality clinical research reviews PRINCETON, N.J., May 11, 2015 /PRNewswire/ -- WIRB-Copernicus Group
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.